National Institutes of Health: Brain Neoplasms trials

The registry lists 102 Brain Neoplasms studies with National Institutes of Health as lead sponsor. 5 are open to participants now and 31 have results posted.

Phase 1 48Phase 2 35Phase 3 2Phase 4 1No phase 29(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent GlioblastomaRecruitingNCT07416188Phase 1/2
• PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN AmplificationsRecruitingNCT06161519Phase 1/2
• 000860: A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) MutationsRecruitingNCT05588141Phase 1/2
• Tumor Related EpilepsyRecruitingNCT02639325
• Evaluation and Treatment of Neurosurgical DisordersRecruitingNCT00060541
• Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral MicrodialysisActive, not recruitingNCT05413304Phase 1Results posted
• Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has SpreadCompletedNCT04631029Phase 1Results posted
• Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction CancersActive, not recruitingNCT04460937Phase 1Results posted
• Immersive Virtual Reality (VR) at the Time of Clinical Evaluation to Improve Psychological Distress and Anxiety in Primary Brain Tumor (PBT) PatientsCompletedNCT04301089Phase 2Results posted
• Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung CancerActive, not recruitingNCT04250545Phase 1Results posted
• Feasibility and Preliminary Efficacy of a Mindfulness-based Intervention for Children and Young Adults With High Grade or High-Risk Cancer and Their CaregiversCompletedNCT03538587Not applicableResults posted
• T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic RadiosurgeryTerminatedNCT03190967Phase 1/2Results posted
• Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS CancersTerminatedNCT03173950Phase 2Results posted
• Protein Phosphatase 2A Inhibitor, in Recurrent GlioblastomaCompletedNCT03027388Phase 2Results posted
• Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain MetastasesActive, not recruitingNCT02993146Phase 1Results posted
• Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain MetastasesActive, not recruitingNCT02971501Phase 2Results posted
• Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and GlioblastomaTerminatedNCT02942264Phase 1/2Results posted
• Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain MetastasesCompletedNCT02595905Phase 2Results posted
• Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine TumorsActive, not recruitingNCT02589522Phase 1Results posted
• Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior BevacizumabCompletedNCT01931098Phase 2Results posted
• Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma MultiformeCompletedNCT01648348Phase 1/2Results posted
• Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast CancerCompletedNCT01622868Phase 2Results posted
• Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain TumorsCompletedNCT01609790Phase 2Results posted
• CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIIICompletedNCT01454596Phase 1/2Results posted
• Phase I-II Everolimus and Sorafenib in Recurrent High-Grade GliomasCompletedNCT01434602Phase 1/2Results posted
• Carboplatin and Bevacizumab for Recurrent EpendymomaCompletedNCT01295944Phase 2Results posted
• RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast CancerTerminatedNCT01217411Phase 1/2Results posted
• Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant GliomaCompletedNCT01051557Phase 1/2Results posted
• Dose-Dense Temozolomide + Lapatinib for Recurrent EpendymomaCompletedNCT00826241Phase 2Results posted
• Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck CancerCompletedNCT00492089Phase 2Results posted
• Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or GliosarcomaCompletedNCT00433381Phase 2Results posted
• Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or GliosarcomaCompletedNCT00423735Phase 2Results posted
• Tandutinib in Treating Patients With Recurrent or Progressive GlioblastomaCompletedNCT00379080Phase 1/2Results posted
• Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent GlioblastomaCompletedNCT00329719Phase 1/2Results posted
• Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain TumorsCompletedNCT00302159Phase 2Results posted
• Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung CancerTerminatedNCT00096265Phase 3Results posted
• Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) TumorsCompletedNCT07374692
• Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or GliosarcomaCompletedNCT04817254Phase 2
• A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast CancerWithdrawnNCT03803761Phase 1/2
• Rare CNS Tumors Outcomes &RiskCompletedNCT03251989
• Cancer and Other Disease Risks in U.S. Nuclear Medicine TechnologistsCompletedNCT02911155
• Natural History of and Specimen Banking for People With Tumors of the Central Nervous SystemCompletedNCT02851706
• Early Life Exposures in AgricultureCompletedNCT02743481
• Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent GlioblastomaCompletedNCT02709226Phase 1
• Biomarker Analysis of Central Nervous System TumorsTerminatedNCT02692898
• Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or MedulloblastomaActive, not recruitingNCT02359565Phase 1
• Feasibility of Identifying a Chinese Study Population and Eligible Pediatric Cancer Cases, and Linking the Two Groups to Assess the Role of Periconceptional Folic Acid Supplements in Risk of Pediatric Cancer.WithdrawnNCT02160795
• Trial Evaluating an Enhanced Physical Activity Intervention to Improve Cognitive Late Effects in Children Treated With Cranial Radiation for Brain TumorsCompletedNCT02153957Phase 2
• Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade GliomaCompletedNCT02101905Phase 1
• Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain MetastasesActive, not recruitingNCT02015117Phase 1
• NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid TumorsCompletedNCT01875601Phase 1
• GRN1005 for Brain Metastases From Breast or Lung CancerWithdrawnNCT01679743Phase 2
• Neuropsychological Changes in Patients Receiving Radiation Therapy for Brain MetastasesCompletedNCT01445483
• Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System TumorsCompletedNCT01445288
• Bevacizumab With or Without Surgery for Adult GlioblastomasWithdrawnNCT01413438Phase 2
• High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent GliomaTerminatedNCT01378481Phase 1
• RO4929097 in Treating Patients With Recurrent Invasive GliomasTerminatedNCT01269411Phase 1
• Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain TumorsCompletedNCT01259479Phase 1
• A Pilot Study of Inpatient Hospice With Procurement of Brain Tumor Tissue on Expiration for Research PurposesTerminatedNCT01251913
• RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell LeukemiaWithdrawnNCT01236586Phase 1
• Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine GliomasCompletedNCT01222754Phase 1
• Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid TumorsCompletedNCT01131234Phase 1
• A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid TumorsWithdrawnNCT01130623Phase 1
• Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma MultiformeTerminatedNCT01122888Phase 1
• Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent GlioblastomaCompletedNCT00979862Phase 1
• Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung CancerTerminatedNCT00937482Phase 1
• Informed Consent in Pediatric Cancer TrialsCompletedNCT00923650
• Pharmacokinetic Studies Participation SurveyCompletedNCT00923468
• An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-grade GliomaTerminatedNCT00880061Phase 1
• Study of Health Effects of Cosmetic Breast AugmentationCompletedNCT00342953
• A Prospective Cohort Study of Occupational Exposures and Cancer Risk Among WomenCompletedNCT00342004
• A Case-Referent Study of Brain Tumors in AdultsCompletedNCT00339300
• AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS TumorsCompletedNCT00326664Phase 1
• Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid TumorsCompletedNCT00303940Phase 1
• Diffusion Tensor MRI to Distinguish Brain Tumor Recurrence From Radiation NecrosisCompletedNCT00285324
• Vorinostat and Temozolomide in Treating Patients With Malignant GliomasActive, not recruitingNCT00268385Phase 1
• Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain TumorsTerminatedNCT00110032Phase 1
• GW572016 to Treat Recurrent Malignant Brain TumorsCompletedNCT00107003Phase 2
• Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain MetastasesCompletedNCT00098605Phase 2
• Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid TumorsCompletedNCT00077454Phase 1
• Surgery Versus Radiosurgery to Treat Metastatic Brain TumorsCompletedNCT00075166Phase 4
• Analysis of Brain Metastasis in Patients With Breast Cancer, With and Without Over-Expression of HER-2CompletedNCT00071383
• Analysis of Brain Metastasis in Patients With Lung CancerCompletedNCT00071344
• Comparison of PET and Proton MRS Imaging to Evaluate Pediatric Brain Tumor ActivityCompletedNCT00067821
• Light Scattering Spectroscopy to Determine Brain TumorsCompletedNCT00067418
• Cilengitide in Treating Children With Refractory Primary Brain TumorsCompletedNCT00063973Phase 1
• Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain TumorsCompletedNCT00052780Phase 1
• Brain Neoplasms, Leukemia and Petrochemical ExposuresCompletedNCT00042445
• Radiation Therapy With or Without Thalidomide in Treating Patients With Brain MetastasesCompletedNCT00033254Phase 3
• Liposomal Doxorubicin in Treating Children With Refractory Solid TumorsCompletedNCT00019630Phase 1
• Stereotactic Radiosurgery in Treating Patients With Brain TumorsCompletedNCT00019578Phase 1
• Phenylbutyrate to Treat Children With Progressive or Recurrent Brain TumorsCompletedNCT00006450Phase 2
• Phase II Randomized Study of Stereotactic Radiosurgery Plus Fractionated Whole-Brain Radiotherapy Vs Fractionated Whole-Brain Radiotherapy Alone for Multiple Primary or Metastatic Brain TumorsStatus unknownNCT00004659Phase 2
• Gene Therapy in Treating Patients With Recurrent or Progressive Brain TumorsCompletedNCT00004080Phase 1
• PET Scan of Brain Metabolism in Relation to Age and DiseaseCompletedNCT00001972
• (1)H-Nuclear Magnetic Resonance Spectroscopic Imaging of the Brain in Patients Who Receive Neurotoxic TherapyCompletedNCT00001807
• Evaluation, Treatment, and Natural History of Children and Young Adults With Cancer or Rare DiseasesCompletedNCT00001686
• A Pilot Study of 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Pediatric Patients With Primary and Metastatic Brain TumorsCompletedNCT00001574
• Phase I and Pharmacokinetic Trial of Phenylbutyrate Given as a Continuous Infusion in Pediatric Patients With Refractory MalignancyCompletedNCT00001565Phase 1
• A Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain TumorsCompletedNCT00001502Phase 1